Engineered extracellular vesicles derived from pluripotent stem cells: a cell-free approach to regenerative medicine

Abstract

The engineered extracellular vesicles (EVs) derived from pluripotent stem cells (PSCs) are a new concept in regenerative medicine. These vesicles are secreted from the embryonic stem cells as well as the induced PSCs (iPSCs) and are involved in the transfer of bioactive molecules required for cell signaling. This review describes the possibilities for their use in the modification of therapeutic approaches in regenerative medicine and targeted therapies. PSCs can differentiate into various cell types that can be useful for tissue engineering or to generate models of diseases in a dish. Compared to cell therapies, engineered EVs are characterized by lower immunogenicity, higher targetability, and improved stability. Some of the applications are angiogenic, tissue restorative, immunomodulatory, and gene therapies for the treatment of certain diseases. iPSC-derived engineered EVs find application in regenerative medicine, drug delivery systems, diagnostics of diseases, and hydrogel systems. In regenerative medicine, they can promote the restoration of cardiac, bone, cartilage, and corneal tissues. Engineered EVs are also employed in drug targeting to particular sites as well as in the diagnosis of diseases based on biomarkers and improving image contrast. Hydrogels that contain EVs provide a depot-based delivery system to slowly release drugs in a controlled manner that enhances tissue repair. Thus, the results described above demonstrate the potential of engineered PSC-EVs for various biomedical applications. Future work will be directed toward expanding the knowledge of engineered PSC-EVs and their possibilities to create new therapeutic approaches based on the functions of these vesicles.

References

[1] Yamanaka S.Pluripotent stem cell-based cell therapy-promise and challenges.Cell Stem Cell. 2020; 27: 523-31. https://doi.org/10.1016/j.stem.2020.09.014.

[2] Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126: 663-76. https://doi.org/10.1016/j.cell.2006.07.024.

[3] Ohnuki M, Takahashi K. Present and future challenges of induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci. 2015; 370: 20140367. https://doi.org/10.1098/rstb.2014.0367.

[4] Cho J, Lee H, Rah W, Chang HJ, Yoon YS. From engineered heart tissue to cardiac organoid.Theranostics. 2022; 12: 2758-72. https://doi.org/10.7150/thno.67661.

[5] Zhao S, Chen J, Wu L, Tao X, Yaqub N, Chang J. Induced pluripotent stem cells for tissue-engineered skeletal muscles. Int J Mol Sci. 2023; 24: 11520. https://doi.org/10.3390/ijms241411520.

[6] van Niel G, D’Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19: 213-28. https://doi.org/10.1038/nrm.2017.125.

[7] Wang AYL. Human induced pluripotent stem cell-derived exosomes as a new therapeutic strategy for various diseases. Int J Mol Sci. 2021; 22: 1769. https://doi.org/10.3390/ijms22041769.

[8] Ulpiano C, da Silva CL, Monteiro GA. Bioengineered mesenchymal-stromal-cell-derived extracellular vesicles as an improved drug delivery system: methods and applications. Biomedicines. 2023; 11: 1231. https://doi.org/10.3390/biomedicines11041231.

[9] Liu C, Bayado N, He D, Li J, Chen H, Li L. et al. Therapeutic applications of extracellular vesicles for myocardial repair. Front Cardiovasc Med. 2021; 8: 758050. https://doi.org/10.3389/fcvm.2021.758050.

[10] Gupta D, Zickler AM, El Andaloussi S. Dosing extracellular vesicles. Adv Drug Deliv Rev. 2021; 178: 113961. https://doi.org/10.1016/j.addr.2021.113961.

[11] Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS. et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282: 1145-7. https://doi.org/10.1126/science.282.5391.1145.

[12] Reubinoff BE, Pera MF, Fong CY, Trounson A, Bongso A. Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. 2000; 18: 399-404. https://doi.org/10.1038/74447.

[13] Shahbazi MN.Mechanisms of human embryo development: from cell fate to tissue shape and back. Development. 2020; 147: 147. https://doi.org/10.1242/dev.190629.

[14] Avila-Gonzalez D, Gidi-Grenat MA, Garcia-Lopez G, Martinez-Juarez A, Molina-Hernandez A, Portillo W. et al. Pluripotent stem cells as a model for human embryogenesis. Cells. 2023; 12: 1192. https://doi.org/10.3390/cells12081192.

[15] Moradi S, Mahdizadeh H, Saric T, Kim J, Harati J, Shahsavarani H. et al. Research and therapy with induced pluripotent stem cells (iPSCs): social, legal, and ethical considerations. Stem Cell Res Ther. 2019; 10: 341. https://doi.org/10.1186/s13287-019-1455-y.

[16] Wang AYL, Loh CYY. Episomal induced pluripotent stem cells: functional and potential therapeutic applications. Cell Transplant. 2019; 28: 112S-31. https://doi.org/10.1177/0963689719886534.

[17] Loh CY, Wang AY, Kao HK, Cardona E, Chuang SH, Wei FC. Episomal induced pluripotent stem cells promote functional recovery of Transected murine peripheral nerve. PLoS One. 2016; 11: e0164696. https://doi.org/10.1371/journal.pone.0164696.

[18] Singh VK, Kalsan M, Kumar N, Saini A, Chandra R. Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol. 2015; 3: 2. https://doi.org/10.3389/fcell.2015.00002.

[19] Aboul-Soud MAM, Alzahrani AJ, Mahmoud A. Induced pluripotent stem cells (iPSCs)-roles in regenerative therapies, disease modelling and drug screening. Cells. 2021; 10: 2319. https://doi.org/10.3390/cells10092319.

[20] Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP. et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005; 122: 947-56. https://doi.org/10.1016/j.cell.2005.08.020.

[21] Miki T, Yasuda SY, Kahn M. Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev Rep. 2011; 7: 836-46. https://doi.org/10.1007/s12015-011-9275-1.

[22] Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat Protoc. 2013; 8: 162-75. https://doi.org/10.1038/nprot.2012.150.

[23] Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K. et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature. 2011; 470: 105-9. https://doi.org/10.1038/nature09691.

[24] Hogrebe NJ, Augsornworawat P, Maxwell KG, Velazco-Cruz L, Millman JR. Targeting the cytoskeleton to direct pancreatic differentiation of human pluripotent stem cells. Nat Biotechnol. 2020; 38: 460-70. https://doi.org/10.1038/s41587-020-0430-6.

[25] Hulme AJ, Maksour S, St-Clair Glover M, Miellet S, Dottori M. Making neurons, made easy: the use of Neurogenin-2 in neuronal differentiation. Stem Cell Rep. 2022; 17: 14-34. https://doi.org/10.1016/j.stemcr.2021.11.015.

[26] Yang SY, Strong N, Gong X, Heggeness MH. Differentiation of nerve-derived adult pluripotent stem cells into osteoblastic and endothelial cells. Spine J. 2017; 17: 277-81. https://doi.org/10.1016/j.spinee.2016.10.002.

[27] Kaitsuka T, Tomizawa K. Cell-penetrating peptide as a means of directing the differentiation of induced-pluripotent stem cells. Int J Mol Sci. 2015; 16: 26667-76. https://doi.org/10.3390/ijms161125986.

[28] Chen H, Zheng K, Qiu M, Yang J. Preparation of astrocytes by directed differentiation of pluripotent stem cells and somatic cell transdifferentiation. Dev Neurobiol. 2023; 83: 282-92. https://doi.org/10.1002/dneu.22929.

[29] Apostolou E, Hochedlinger K. Chromatin dynamics during cellular reprogramming. Nature. 2013; 502: 462-71. https://doi.org/10.1038/nature12749.

[30] Smith ZD, Meissner A. DNA methylation: roles in mammalian development. Nat Rev Genet. 2013; 14: 204-20. https://doi.org/10.1038/nrg3354.

[31] Agostinho de Sousa J, Wong CW, Dunkel I, Owens T, Voigt P, Hodgson A. et al. Epigenetic dynamics during capacitation of naive human pluripotent stem cells. Sci Adv. 2023; 9: eadg1936. https://doi.org/10.1126/sciadv.adg1936.

[32] Zare A, Salehpour A, Khoradmehr A, Bakhshalizadeh S, Najafzadeh V, Almasi-Turk S. et al. Epigenetic modification factors and microRNAs network associated with differentiation of embryonic stem cells and induced pluripotent stem cells toward Cardiomyocytes: a review. Life (Basel). 2023; 13: 13. https://doi.org/10.3390/life13020569.

[33] Kim YJ, Tamadon A, Kim YY, Kang BC, Ku SY. Epigenetic regulation of Cardiomyocyte differentiation from embryonic and induced pluripotent stem cells. Int J Mol Sci. 2021; 22: 8599. https://doi.org/10.3390/ijms22168599.

[34] Godini R, Lafta HY, Fallahi H. Epigenetic modifications in the embryonic and induced pluripotent stem cells. Gene Expr Patterns. 2018; 29: 1-9. https://doi.org/10.1016/j.gep.2018.04.001.

[35] Becker A, Thakur BK, Weiss JM, Kim HS, Peinado H, Lyden D. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016; 30: 836-48. https://doi.org/10.1016/j.ccell.2016.10.009.

[36] Li S, Li W, Wu X, Zhang B, Liu L, Yin L. Immune cell-derived extracellular vesicles for precision therapy of inflammatory-related diseases. J Control Release. 2024; 368: 533-47. https://doi.org/10.1016/j.jconrel.2024.03.007.

[37] Yang P, Peng Y, Feng Y, Xu Z, Feng P, Cao J. et al. Immune cell-derived extracellular vesicles-new strategies in cancer immunotherapy. Front Immunol. 2021; 12: 771551. https://doi.org/10.3389/fimmu.2021.771551.

[38] Zhang X, Zhang H, Gu J, Zhang J, Shi H, Qian H. et al. Engineered extracellular vesicles for cancer therapy. Adv Mater. 2021; 33: e2005709. https://doi.org/10.1002/adma.202005709.

[39] Gurrieri E, D’Agostino VG. Strategies to functionalize extracellular vesicles against HER2 for anticancer activity. Extracell Vesicles Circ Nucl Acids. 2022; 3: 93-101. https://doi.org/10.20517/evcna.2022.07.

[40] Sitia L, Sevieri M, Signati L, Bonizzi A, Chesi A, Mainini F. et al. HER-2-targeted nanoparticles for breast cancer diagnosis and treatment. Cancers (Basel). 2022; 14: 2424. https://doi.org/10.3390/cancers14102424.

[41] Ziegler JN, Tian C. Engineered extracellular vesicles: emerging therapeutic strategies for translational applications. Int J Mol Sci. 2023; 24: 15206. https://doi.org/10.3390/ijms242015206.

[42] Nieland L, Mahjoum S, Grandell E, Breyne K, Breakefield XO. Engineered EVs designed to target diseases of the CNS. J Control Release. 2023; 356: 493-506. https://doi.org/10.1016/j.jconrel.2023.03.009.

[43] Lopez K, Lai SWT, Lopez Gonzalez EJ, Davila RG, Shuck SC. Extracellular vesicles: a dive into their role in the tumor microenvironment and cancer progression. Front Cell Dev Biol. 2023; 11: 1154576. https://doi.org/10.3389/fcell.2023.1154576.

[44] Kumar MA, Baba SK, Sadida HQ, Marzooqi SA, Jerobin J, Altemani FH. et al. Extracellular vesicles as tools and targets in therapy for diseases. Signal Transduct Target Ther. 2024; 9: 27. https://doi.org/10.1038/s41392-024-01735-1.

[45] Wang L, Yu X, Zhou J, Su C. Extracellular vesicles for drug delivery in cancer treatment. Biol Proced Online. 2023; 25: 28. https://doi.org/10.1186/s12575-023-00220-3.

[46] Ming-Kun C, Zi-Xian C, Mao-Ping C, Hong C, Zhuang-Fei C, Shan-Chao Z. Engineered extracellular vesicles: a new approach for targeted therapy of tumors and overcoming drug resistance. Cancer Commun (Lond). 2024; 44: 205-25. https://doi.org/10.1002/cac2.12518.

[47] Keshtkar S, Azarpira N, Ghahremani MH. Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine. Stem Cell Res Ther. 2018; 9: 63. https://doi.org/10.1186/s13287-018-0791-7.

[48] Abebaw D, Akelew Y, Adugna A, Teffera ZH, Tegegne BA, Fenta A. et al. Extracellular vesicles: immunomodulation, diagnosis, and promising therapeutic roles for rheumatoid arthritis. Front Immunol. 2024; 15: 1499929. https://doi.org/10.3389/fimmu.2024.1499929.

[49] Aloi N, Drago G, Ruggieri S, Cibella F, Colombo P, Longo V. Extracellular vesicles and immunity: At the crossroads of cell communication. Int J Mol Sci. 2024; 25: 1205. https://doi.org/10.3390/ijms25021205.

[50] Gurung S, Perocheau D, Touramanidou L, Baruteau J. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun Signal. 2021; 19: 47. https://doi.org/10.1186/s12964-021-00730-1.

[51] Jin Y, Ma L, Zhang W, Yang W, Feng Q, Wang H. Extracellular signals regulate the biogenesis of extracellular vesicles. Biol Res. 2022; 55: 35. https://doi.org/10.1186/s40659-022-00405-2.

[52] Martin C, Ligat G, Malnou CE. The Yin and the Yang of extracellular vesicles during viral infections. Biom J. 2023; 47: 100659. https://doi.org/10.1016/j.bj.2023.100659.

[53] Battistelli M, Falcieri E. Apoptotic bodies: particular extracellular vesicles involved in intercellular communication. Biology (Basel). 2020; 9: 21. https://doi.org/10.3390/biology9010021.

[54] Li Z, Wang X, Wang X, Yi X, Wong YK, Wu J. et al. Research progress on the role of extracellular vesicles in neurodegenerative diseases. Transl Neurodegener. 2023; 12: 43. https://doi.org/10.1186/s40035-023-00375-9.

[55] Zaborowski MP, Balaj L, Breakefield XO, Lai CP. Extracellular vesicles: composition, biological relevance, and methods of study. Bioscience. 2015; 65: 783-97. https://doi.org/10.1093/biosci/biv084.

[56] Sen S, Xavier J, Kumar N, Ahmad MZ, Ranjan OP. Exosomes as natural nanocarrier-based drug delivery system: recent insights and future perspectives. 3 Biotech. 2023; 13: 101. https://doi.org/10.1007/s13205-023-03521-2.

[57] Koh HB, Kim HJ, Kang SW, Yoo TH. Exosome-based drug delivery: translation from bench to clinic.Pharmaceutics. 2023; 15: 2042. https://doi.org/10.3390/pharmaceutics15082042.

[58] Stahl AL, Johansson K, Mossberg M, Kahn R, Karpman D. Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. Pediatr Nephrol. 2019; 34: 11-30. https://doi.org/10.1007/s00467-017-3816-z.

[59] Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest. 2001; 108: 957-62. https://doi.org/10.1172/JCI200114122.

[60] Arandjelovic S, Ravichandran KS. Phagocytosis of apoptotic cells in homeostasis. Nat Immunol. 2015; 16: 907-17. https://doi.org/10.1038/ni.3253.

[61] Miao X, Wu X, You W, He K, Chen C, Pathak JL. et al. Tailoring of apoptotic bodies for diagnostic and therapeutic applications: advances, challenges, and prospects. J Transl Med. 2024; 22: 810. https://doi.org/10.1186/s12967-024-05451-w.

[62] Yu L, Zhu G, Zhang Z, Yu Y, Zeng L, Xu Z. et al. Apoptotic bodies: bioactive treasure left behind by the dying cells with robust diagnostic and therapeutic application potentials. J Nanobiotechnology. 2023; 21: 218. https://doi.org/10.1186/s12951-023-01969-1.

[63] Salehi M, Kamali MJ, Arab D, Safaeian N, Ashuori Z, Maddahi M. et al. Exosomal microRNAs in regulation of tumor cells resistance to apoptosis. Biochem Biophys Rep. 2024; 37: 101644. https://doi.org/10.1016/j.bbrep.2024.101644.

[64] Chen X, Li Y, Li M, Xie Y, Wang K, Zhang L. et al. Exosomal miRNAs assist in the crosstalk between tumor cells and immune cells and its potential therapeutics. Life Sci. 2023; 329: 121934. https://doi.org/10.1016/j.lfs.2023.121934.

[65] Mosquera-Heredia MI, Morales LC, Vidal OM, Barcelo E, Silvera-Redondo C, Velez JI. et al. Exosomes: potential disease biomarkers and new therapeutic targets. Biomedicines. 2021; 9: 1061. https://doi.org/10.3390/biomedicines9081061.

[66] Lou C, Ma X, Chen Z, Zhao Y, Yao Q, Zhou C. et al. The mtDNA fragments within exosomes might be novel diagnostic biomarkers of non-small cell lung cancer. Pathol Res Pract. 2023; 249: 154718. https://doi.org/10.1016/j.prp.2023.154718.

[67] Tetta C, Bruno S, Fonsato V, Deregibus MC, Camussi G. The role of microvesicles in tissue repair.Organ. 2011; 7: 105-15. https://doi.org/10.4161/org.7.2.15782.

[68] Li X, Liu Y, Liu X, Du J, Bhawal UK, Xu J. et al. Advances in the therapeutic effects of apoptotic bodies on systemic diseases. Int J Mol Sci. 2022; 23: 8202. https://doi.org/10.3390/ijms23158202.

[69] Andaloussi SEL, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12: 347-57. https://doi.org/10.1038/nrd3978.

[70] Kanellopoulos JM, Rieux-Laucat F, Ojcius DM. Biological functions of extracellular vesicles from mammalian cells. Biom J. 2024; 47: 100788. https://doi.org/10.1016/j.bj.2024.100788.

[71] Kattner AA. Communicating across distances-biological functions of extracellular vesicles. Biom J. 2024; 47: 100792. https://doi.org/10.1016/j.bj.2024.100792.

[72] Burlingham WJ. Extracellular vesicles in fetal-maternal immune tolerance. Biom J. 2024; 47: 100785. https://doi.org/10.1016/j.bj.2024.100785.

[73] Wang Y, Xu R, Yan Y, He B, Miao C, Fang Y. et al. Exosomes-mediated Signaling pathway: a new direction for treatment of organ ischemia-reperfusion injury. Biomedicines. 2024; 12: 12. https://doi.org/10.3390/biomedicines12020353.

[74] Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A. et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes (Basel). 2013; 4: 152-70. https://doi.org/10.3390/genes4020152.

[75] Jiang J, Li J, Zhou X, Zhao X, Huang B, Qin Y. Exosomes regulate the epithelial-mesenchymal transition in cancer. Front Oncol. 2022; 12: 864980. https://doi.org/10.3389/fonc.2022.864980.

[76] Iranpanah A, Kooshki L, Moradi SZ, Saso L, Fakhri S, Khan H. The exosome-mediated PI3K/Akt/mTOR Signaling pathway in neurological diseases. Pharmaceutics. 2023; 15: 1006. https://doi.org/10.3390/pharmaceutics15031006.

[77] Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in angiogenesis and anti-angiogenic therapy in cancers. Int J Mol Sci. 2020; 21: 5840. https://doi.org/10.3390/ijms21165840.

[78] Zelli V, Compagnoni C, Capelli R, Corrente A, Di Vito NM, Zazzeroni F. et al. Role of exosomal microRNAs in cancer therapy and drug resistance mechanisms: focus on hepatocellular carcinoma. Front Oncol. 2022; 12: 940056. https://doi.org/10.3389/fonc.2022.940056.

[79] Marconi GD, Diomede F, Trubiani O, Porcheri C, Mitsiadis TA. Exosomes as carriers for notch molecules. Methods Mol Biol. 2022; 2472: 197-208. https://doi.org/10.1007/978-1-0716-2201-8_16.

[80] Colangelo T, Panelli P, Mazzarelli F, Tamiro F, Melocchi V, De Santis E. et al. Extracellular vesicle microRNAs contribute to notch signaling pathway in T-cell acute lymphoblastic leukemia. Mol Cancer. 2022; 21: 226. https://doi.org/10.1186/s12943-022-01698-3.

[81] Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE. et al. New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood. 2010; 116: 2385-94. https://doi.org/10.1182/blood-2009-08-239228.

[82] Liao FL, Tan L, Liu H, Wang JJ, Ma XT, Zhao B. et al. Hematopoietic stem cell-derived exosomes promote hematopoietic differentiation of mouse embryonic stem cells in vitro via inhibiting the miR126/Notch1 pathway. Acta Pharmacol Sin. 2018; 39: 552-60. https://doi.org/10.1038/aps.2017.130.

[83] Awadasseid A, Wu Y, Zhang W. Extracellular vesicles (exosomes) as immunosuppressive mediating variables in tumor and chronic inflammatory microenvironments. Cells. 2021; 10: 2533. https://doi.org/10.3390/cells10102533.

[84] Filipazzi P, Burdek M, Villa A, Rivoltini L, Huber V. Recent advances on the role of tumor exosomes in immunosuppression and disease progression. Semin Cancer Biol. 2012; 22: 342-9. https://doi.org/10.1016/j.semcancer.2012.02.005.

[85] Altei WF, Pachane BC, Dos Santos PK, Ribeiro LNM, Sung BH, Weaver AM. et al. Inhibition of alphavbeta3 integrin impairs adhesion and uptake of tumor-derived small extracellular vesicles. Cell Commun Signal. 2020; 18: 158. https://doi.org/10.1186/s12964-020-00630-w.

[86] Niland S, Eble JA. Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol. 2012; 2012: 125278, 1-25. https://doi.org/10.1155/2012/125278.

[87] Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008; 8: 604-17. https://doi.org/10.1038/nrc2353.

[88] Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007; 35: 495-516. https://doi.org/10.1080/01926230701320337.

[89] Lam AL, Heit B. Having an old friend for dinner: the interplay between apoptotic cells and efferocytes. Cells. 2021; 10: 1265.

[90] Birge RB, Boeltz S, Kumar S, Carlson J, Wanderley J, Calianese D. et al. Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. Cell Death Differ. 2016; 23: 962-78. https://doi.org/10.1038/cdd.2016.11.

[91] Park SY, Kim IS. Engulfment signals and the phagocytic machinery for apoptotic cell clearance. Exp Mol Med. 2017; 49: e331. https://doi.org/10.1038/emm.2017.52.

[92] Braig ZV. Personalized medicine: from diagnostic to adaptive. Biom J. 2022; 45: 132-42. https://doi.org/10.1016/j.bj.2019.05.004.

[93] Tang N.Exosomes in multiple sclerosis and Alzheimer’s disease-adversary and ally. Biom J. 2023; 47: 100665. https://doi.org/10.1016/j.bj.2023.100665.

[94] Kim KH, Jo JH, Cho HJ, Park TS, Kim TM. Therapeutic potential of stem cell-derived extracellular vesicles in osteoarthritis: preclinical study findings. Lab Anim Res. 2020; 36: 10. https://doi.org/10.1186/s42826-020-00043-3.

[95] Meng WT, Guo HD. Small extracellular vesicles derived from induced pluripotent stem cells in the treatment of myocardial injury. Int J Mol Sci. 2023; 24: 4577. https://doi.org/10.3390/ijms24054577.

[96] Barreca MM, Cancemi P, Geraci F. Mesenchymal and induced pluripotent stem cells-derived extracellular vesicles: the new frontier for regenerative medicine? Cells. 2020; 9: 1163.

[97] Yang M, Peng GH. The molecular mechanism of human stem cell-derived extracellular vesicles in retinal repair and regeneration. Stem Cell Res Ther. 2023; 14: 84. https://doi.org/10.1186/s13287-023-03319-2.

[98] Wang Z, Knight R, Stephens P, Ongkosuwito EM, Wagener F, Von den Hoff JW. Stem cells and extracellular vesicles to improve preclinical orofacial soft tissue healing. Stem Cell Res Ther. 2023; 14: 203. https://doi.org/10.1186/s13287-023-03423-3.

[99] Yin L, Liu X, Shi Y, Ocansey DKW, Hu Y, Li X. et al. Therapeutic advances of stem cell-derived extracellular vesicles in regenerative medicine.Cells. 2020; 9: 707. https://doi.org/10.3390/cells9030707.

[100] Wang Y, Zhang L, Li Y, Chen L, Wang X, Guo W. et al. Exosomes/microvesicles from induced pluripotent stem cells deliver cardioprotective miRNAs and prevent cardiomyocyte apoptosis in the ischemic myocardium. Int J Cardiol. 2015; 192: 61-9. https://doi.org/10.1016/j.ijcard.2015.05.020.

[101] Xuan W, Wang L, Xu M, Weintraub NL, Ashraf M. miRNAs in extracellular vesicles from iPS-derived cardiac progenitor cells effectively reduce fibrosis and promote angiogenesis in infarcted heart. Stem Cells Int. 2019; 2019: 1-14. https://doi.org/10.1155/2019/3726392.

[102] Wei F, Cao C, Xu X, Wang J. Diverse functions of miR-373 in cancer. J Transl Med. 2015; 13: 162. https://doi.org/10.1186/s12967-015-0523-z.

[103] Ji Y, Ma Y, Chen X, Ji X, Gao J, Zhang L. et al. Microvesicles released from human embryonic stem cell derived-mesenchymal stem cells inhibit proliferation of leukemia cells. Oncol Rep. 2017; 38: 1013-20. https://doi.org/10.3892/or.2017.5729.

[104] Zhang L, Gao J, Chen T, Chen X, Ji X, Ye K. et al. Microvesicles derived from human embryonic neural stem cells inhibit the apoptosis of HL-1 Cardiomyocytes by promoting autophagy and regulating AKT and mTOR via transporting HSP-70. Stem Cells Int. 2019; 2019: 1-15. https://doi.org/10.1155/2019/6452684.

[105] Yan Y, Wu R, Bo Y, Zhang M, Chen Y, Wang X. et al. Induced pluripotent stem cells-derived microvesicles accelerate deep second-degree burn wound healing in mice through miR-16-5p-mediated promotion of keratinocytes migration. Theranostics. 2020; 10: 9970-83. https://doi.org/10.7150/thno.46639.

[106] Bakhshandeh B, Jahanafrooz Z, Allahdadi S, Daryani S, Dehghani Z, Sadeghi M. et al. Transcriptomic and in vivo approaches introduced human iPSC-derived microvesicles for skin rejuvenation. Sci Rep. 2023; 13: 9963. https://doi.org/10.1038/s41598-023-36162-9.

[107] Pang Y, Ma M, Wang D, Xia J, Wang X, Hou L. et al. Embryonic stem cell-derived exosomes attenuate transverse aortic constriction induced heart failure by increasing angiogenesis. Front Cardiovasc Med. 2021; 8: 638771. https://doi.org/10.3389/fcvm.2021.638771.

[108] Wang N, Li X, Zhong Z, Qiu Y, Liu S, Wu H. et al. 3D hESC exosomes enriched with miR-6766-3p ameliorates liver fibrosis by attenuating activated stellate cells through targeting the TGFbetaRII-SMADS pathway. J Nanobiotechnology. 2021; 19: 437. https://doi.org/10.1186/s12951-021-01138-2.

[109] Liu Q, Bi Y, Song S, Zhu K, Qiao X, Wang H. et al. Exosomal miR-17-5p from human embryonic stem cells prevents pulmonary fibrosis by targeting thrombospondin-2. Stem Cell Res Ther. 2023; 14: 234. https://doi.org/10.1186/s13287-023-03449-7.

[110] Deng M, Xiao H, Peng H, Yuan H, Xu Y, Zhang G. et al. Preservation of neuronal functions by exosomes derived from different human neural cell types under ischemic conditions. Eur J Neurosci. 2018; 47: 150-7. https://doi.org/10.1111/ejn.13784.

[111] Huang X, Zhao Z, Zhan W, Deng M, Wu X, Chen Z. et al. miR-21-5p enriched exosomes from human embryonic stem cells promote Osteogenesis via YAP1 modulation. Int J Nanomedicine. 2024; 19: 13095-112. https://doi.org/10.2147/IJN.S484751.

[112] Singla DK, Johnson TA, Tavakoli DZ. Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced Pyroptosis in doxorubicin-induced cardiomyopathy. Cells. 2019; 8: 8. https://doi.org/10.3390/cells8101224.

[113] Gao Y, Li H, Qin C, Yang B, Ke Y. Embryonic stem cells-derived exosomes enhance retrodifferentiation of retinal Muller cells by delivering BDNF protein to activate Wnt pathway. Immunobiology. 2022; 227: 152211. https://doi.org/10.1016/j.imbio.2022.152211.

[114] Zhou S, Abdouh M, Arena V, Arena M, Arena GO. Reprogramming malignant cancer cells toward a benign phenotype following exposure to human embryonic stem cell microenvironment. PLoS One. 2017; 12: e0169899. https://doi.org/10.1371/journal.pone.0169899.

[115] Chen B, Sun Y, Zhang J, Zhu Q, Yang Y, Niu X. et al. Human embryonic stem cell-derived exosomes promote pressure ulcer healing in aged mice by rejuvenating senescent endothelial cells. Stem Cell Res Ther. 2019; 10: 142. https://doi.org/10.1186/s13287-019-1253-6.

[116] Khan M, Nickoloff E, Abramova T, Johnson J, Verma SK, Krishnamurthy P. et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res. 2015; 117: 52-64. https://doi.org/10.1161/CIRCRESAHA.117.305990.

[117] Wang Y, Yu D, Liu Z, Zhou F, Dai J, Wu B. et al. Exosomes from embryonic mesenchymal stem cells alleviate osteoarthritis through balancing synthesis and degradation of cartilage extracellular matrix. Stem Cell Res Ther. 2017; 8: 189. https://doi.org/10.1186/s13287-017-0632-0.

[118] Yu Y, Li W, Xian T, Tu M, Wu H, Zhang J. Human embryonic stem-cell-derived exosomes repress NLRP3 Inflammasome to alleviate Pyroptosis in nucleus Pulposus cells by transmitting miR-302c. Int J Mol Sci. 2023; 24: 7664. https://doi.org/10.3390/ijms24087664.

[119] Dessouki FBA, Kukreja RC, Singla DK.Stem cell-derived exosomes ameliorate doxorubicin-induced muscle toxicity through counteracting Pyroptosis. Pharmaceuticals (Basel). 2020; 13: 450. https://doi.org/10.3390/ph13120450.

[120] Bae YU, Son Y, Kim CH, Kim KS, Hyun SH, Woo HG. et al. Embryonic stem cell-derived mmu-miR-291a-3p inhibits cellular senescence in human dermal fibroblasts through the TGF-beta receptor 2 pathway. J Gerontol A Biol Sci Med Sci. 2019; 74: 1359-67. https://doi.org/10.1093/gerona/gly208.

[121] Gao L, Wang L, Wei Y, Krishnamurthy P, Walcott GP, Menasche P. et al. Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine. Sci Transl Med. 2020; 12: 1318. https://doi.org/10.1126/scitranslmed.aay1318.

[122] Santoso MR, Ikeda G, Tada Y, Jung JH, Vaskova E, Sierra RG. et al. Exosomes from induced pluripotent stem cell-derived Cardiomyocytes promote autophagy for myocardial repair. J Am Heart Assoc. 2020; 9: e014345. https://doi.org/10.1161/JAHA.119.014345.

[123] Zhao M, Nakada Y, Wei Y, Bian W, Chu Y, Borovjagin AV. et al. Cyclin D2 overexpression enhances the efficacy of human induced pluripotent stem cell-derived Cardiomyocytes for myocardial repair in a swine model of myocardial infarction. Circulation. 2021; 144: 210-28. https://doi.org/10.1161/CIRCULATIONAHA.120.049497.

[124] Chen M, Chen J, Huang W, Li C, Luo H, Xue Z. et al. Exosomes from human induced pluripotent stem cells derived mesenchymal stem cells improved myocardial injury caused by severe acute pancreatitis through activating Akt/Nrf2/HO-1 axis. Cell Cycle. 2022; 21: 1578-89. https://doi.org/10.1080/15384101.2022.2057762.

[125] Li H, Wang L, Ma T, Liu Z, Gao L. Exosomes secreted by endothelial cells derived from human induced pluripotent stem cells improve recovery from myocardial infarction in mice. Stem Cell Res Ther. 2023; 14: 278. https://doi.org/10.1186/s13287-023-03462-w.

[126] Wang L, Chen P, Pan Y, Wang Z, Xu J, Wu X. et al. Injectable photocurable Janus hydrogel delivering hiPSC cardiomyocyte-derived exosome for post-heart surgery adhesion reduction. Sci Adv. 2023; 9: eadh1753. https://doi.org/10.1126/sciadv.adh1753.

[127] Nong K, Wang W, Niu X, Hu B, Ma C, Bai Y. et al. Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. Cytotherapy. 2016; 18: 1548-59. https://doi.org/10.1016/j.jcyt.2016.08.002.

[128] Du Y, Li D, Han C, Wu H, Xu L, Zhang M. et al. Exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells (hiPSC-MSCs) protect liver against hepatic ischemia/reperfusion injury via activating sphingosine kinase and Sphingosine-1-phosphate Signaling pathway. Cell Physiol Biochem. 2017; 43: 611-25. https://doi.org/10.1159/000480533.

[129] Lim SW, Kim KW, Kim BM, Shin YJ, Luo K, Quan Y. et al. Alleviation of renal ischemia/reperfusion injury by exosomes from induced pluripotent stem cell-derived mesenchymal stem cells. Korean J Intern Med. 2022; 37: 411-24. https://doi.org/10.3904/kjim.2020.438.

[130] Hu GW, Li Q, Niu X, Hu B, Liu J, Zhou SM. et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res Ther. 2015; 6: 10. https://doi.org/10.1186/scrt546.

[131] Ye M, Ni Q, Qi H, Qian X, Chen J, Guo X. et al. Exosomes derived from human induced pluripotent stem cells-endothelia cells promotes postnatal angiogenesis in mice bearing ischemic limbs. Int J Biol Sci. 2019; 15: 158-68. https://doi.org/10.7150/ijbs.28392.

[132] Zhang J, Guan J, Niu X, Hu G, Guo S, Li Q. et al. Exosomes released from human induced pluripotent stem cells-derived MSCs facilitate cutaneous wound healing by promoting collagen synthesis and angiogenesis. J Transl Med. 2015; 13: 49. https://doi.org/10.1186/s12967-015-0417-0.

[133] Kobayashi H, Ebisawa K, Kambe M, Kasai T, Suga H, Nakamura K. et al. Editors’ choice effects of exosomes derived from the induced pluripotent stem cells on skin wound healing. Nagoya J Med Sci. 2018; 80: 141-53. https://doi.org/10.18999/nagjms.80.2.141.

[134] Lu M, Peng L, Ming X, Wang X, Cui A, Li Y. et al. Enhanced wound healing promotion by immune response-free monkey autologous iPSCs and exosomes vs. their allogeneic counterparts. EBioMedicine. 2019; 42: 443-57. https://doi.org/10.1016/j.ebiom.2019.03.011.

[135] Bo Y, Yang L, Liu B, Tian G, Li C, Zhang L. et al. Exosomes from human induced pluripotent stem cells-derived keratinocytes accelerate burn wound healing through miR-762 mediated promotion of keratinocytes and endothelial cells migration. J Nanobiotechnology. 2022; 20: 291. https://doi.org/10.1186/s12951-022-01504-8.

[136] Li J, Gao H, Xiong Y, Wang L, Zhang H, He F. et al. Enhancing cutaneous wound healing based on human induced neural stem cell-derived exosomes. Int J Nanomedicine. 2022; 17: 5991-6006. https://doi.org/10.2147/IJN.S377502.

[137] Yoon J, Lee SK, Park A, Lee J, Jung I, Song KB. et al. Exosome from IFN-gamma-primed induced pluripotent stem cell-derived mesenchymal stem cells improved skin inflammation and barrier function. Int J Mol Sci. 2023; 24: 11635. https://doi.org/10.3390/ijms241411635.

[138] Sharma P, Mesci P, Carromeu C, McClatchy DR, Schiapparelli L, Yates JR, 3rd. et al. Exosomes regulate neurogenesis and circuit assembly. Proc Natl Acad Sci USA. 2019; 116: 16086-94. https://doi.org/10.1073/pnas.1902513116.

[139] Podvin S, Jones A, Liu Q, Aulston B, Mosier C, Ames J. et al. Mutant Presenilin 1 dysregulates Exosomal proteome cargo produced by human-induced pluripotent stem cell neurons. ACS Omega. 2021; 6: 13033-56. https://doi.org/10.1021/acsomega.1c00660.

[140] Pan J, Zhao M, Yi X, Tao J, Li S, Jiang Z. et al. Acellular nerve grafts supplemented with induced pluripotent stem cell-derived exosomes promote peripheral nerve reconstruction and motor function recovery. Bioact Mater. 2022; 15: 272-87. https://doi.org/10.1016/j.bioactmat.2021.12.004.

[141] Li J, Jing YL, Bai F, Wu Y, Wang LM, Yan YT. et al. Induced pluripotent stem cells as natural biofactories for exosomes carrying miR-199b-5p in the treatment of spinal cord injury. Front Pharmacol. 2023; 13: 13. https://doi.org/10.3389/fphar.2022.1078761.

[142] Lu G, Su X, Wang L, Leung CK, Zhou J, Xiong Z. et al. Neuroprotective effects of human-induced pluripotent stem cell-derived mesenchymal stem cell extracellular vesicles in ischemic stroke models. Biomedicines. 2023; 11: 2550. https://doi.org/10.3390/biomedicines11092550.

[143] Zhang J, Liu X, Li H, Chen C, Hu B, Niu X. et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. Stem Cell Res Ther. 2016; 7: 136. https://doi.org/10.1186/s13287-016-0391-3.

[144] Qi X, Zhang J, Yuan H, Xu Z, Li Q, Niu X. et al. Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and Osteogenesis in osteoporotic rats. Int J Biol Sci. 2016; 12: 836-49. https://doi.org/10.7150/ijbs.14809.

[145] Liu X, Li Q, Niu X, Hu B, Chen S, Song W. et al. Exosomes secreted from human-induced pluripotent stem cell-derived mesenchymal stem cells prevent osteonecrosis of the femoral head by promoting angiogenesis. Int J Biol Sci. 2017; 13: 232-44. https://doi.org/10.7150/ijbs.16951.

[146] Zhu Y, Wang Y, Zhao B, Niu X, Hu B, Li Q. et al. Comparison of exosomes secreted by induced pluripotent stem cell-derived mesenchymal stem cells and synovial membrane-derived mesenchymal stem cells for the treatment of osteoarthritis. Stem Cell Res Ther. 2017; 8: 64. https://doi.org/10.1186/s13287-017-0510-9.

[147] Wang S, Hou Y, Li X, Song Z, Sun B, Li X. et al. Comparison of exosomes derived from induced pluripotent stem cells and mesenchymal stem cells as therapeutic nanoparticles for treatment of corneal epithelial defects. Aging (Albany NY). 2020; 12: 19546-62. https://doi.org/10.18632/aging.103904.

[148] Han JW, Chang HS, Yang JY, Choi HS, Park HS, Jun HO, et al. Intravitreal Administration of Retinal Organoids-Derived Exosomes Alleviates Photoreceptor Degeneration in Royal College of surgeons rats by targeting the mitogen-activated protein kinase pathway. Int J Mol Sci. 2023; 24: 12068. https://doi.org/10.3390/ijms241512068.

[149] Zhang L, Ma Y, Xie X, Du C, Zhang Y, Qin S. et al. Human pluripotent stem cell-mesenchymal stem cell-derived exosomes promote ovarian granulosa cell proliferation and attenuate cell apoptosis induced by cyclophosphamide in a POI-like mouse model. Molecules. 2023; 28: 2112. https://doi.org/10.3390/molecules28052112.

[150] Li X, Zhang H, Wang X, Lu M, Ding Q, Chen AF. et al. iPSC-derived exosomes promote angiogenesis in naturally aged mice. Aging (Albany NY). 2023; 15: 5854-72. https://doi.org/10.18632/aging.204845.

[151] Herrmann IK, Wood MJA, Fuhrmann G. Extracellular vesicles as a next-generation drug delivery platform. Nat Nanotechnol. 2021; 16: 748-59. https://doi.org/10.1038/s41565-021-00931-2.

[152] Ceccotti E, Saccu G, Herrera Sanchez MB, Bruno S. Naive or engineered extracellular vesicles from different cell sources: therapeutic tools for kidney diseases.Pharmaceutics. 2023; 15: 1715. https://doi.org/10.3390/pharmaceutics15061715.

[153] Liu Q, Li D, Pan X, Liang Y. Targeted therapy using engineered extracellular vesicles: principles and strategies for membrane modification. J Nanobiotechnology. 2023; 21: 334. https://doi.org/10.1186/s12951-023-02081-0.

[154] Xiao Y, Tian J, Wu WC, Gao YH, Guo YX, Song SJ. et al. Targeting central nervous system extracellular vesicles enhanced triiodothyronine remyelination effect on experimental autoimmune encephalomyelitis. Bioact Mater. 2022; 9: 373-84. https://doi.org/10.1016/j.bioactmat.2021.07.017.

[155] Ginini L, Billan S, Fridman E, Gil Z. Insight into extracellular vesicle-cell communication: from cell recognition to intracellular fate. Cells. 2022; 11: 1375. https://doi.org/10.3390/cells11091375.

[156] Choi H, Choi Y, Yim HY, Mirzaaghasi A, Yoo JK, Choi C. Biodistribution of exosomes and engineering strategies for targeted delivery of therapeutic exosomes. Tissue Eng Regen Med. 2021; 18: 499-511. https://doi.org/10.1007/s13770-021-00361-0.

[157] Kuipers ME, Nolte-’t Hoen ENM, van der Ham AJ, Ozir-Fazalalikhan A, Nguyen DL, de Korne CM. et al. DC-SIGN mediated internalisation of glycosylated extracellular vesicles from Schistosoma mansoni increases activation of monocyte-derived dendritic cells. J Extracell Vesicles. 2020; 9: 1753420. https://doi.org/10.1080/20013078.2020.1753420.

[158] Zhang CX, Huang DJ, Baloche V, Zhang L, Xu JX, Li BW. et al. Galectin-9 promotes a suppressive microenvironment in human cancer by enhancing STING degradation. Oncogenesis. 2020; 9: 65. https://doi.org/10.1038/s41389-020-00248-0.

[159] Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29: 341-5. https://doi.org/10.1038/nbt.1807.

[160] Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N. et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013; 21: 185-91. https://doi.org/10.1038/mt.2012.180.

[161] Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017; 266: 8-16. https://doi.org/10.1016/j.jconrel.2017.09.013.

[162] Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021; 278: 121137. https://doi.org/10.1016/j.biomaterials.2021.121137.

[163] Kim M, Kim G, Hwang DW, Lee M. Delivery of high mobility group Box-1 siRNA using brain-targeting exosomes for ischemic stroke therapy. J Biomed Nanotechnol. 2019; 15: 2401-12. https://doi.org/10.1166/jbn.2019.2866.

[164] Wang J, Li W, Lu Z, Zhang L, Hu Y, Li Q. et al. The use of RGD-engineered exosomes for enhanced targeting ability and synergistic therapy toward angiogenesis. Nanoscale. 2017; 9: 15598-605. https://doi.org/10.1039/C7NR04425A.

[165] Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL. et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018; 14: 195-204. https://doi.org/10.1016/j.nano.2017.09.011.

[166] Tian T, Zhang HX, He CP, Fan S, Zhu YL, Qi C. et al. Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy. Biomaterials. 2018; 150: 137-49. https://doi.org/10.1016/j.biomaterials.2017.10.012.

[167] Wang M, Altinoglu S, Takeda YS, Xu Q. Integrating protein engineering and bioorthogonal click conjugation for extracellular vesicle modulation and intracellular delivery. PLoS One. 2015; 10:e0141860. https://doi.org/10.1371/journal.pone.0141860.

[168] Gao X, Ran N, Dong X, Zuo B, Yang R, Zhou Q. et al. Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy. Sci Transl Med. 2018; 10: 10. https://doi.org/10.1126/scitranslmed.aat0195.

[169] Wan S, Zhang L, Wang S, Liu Y, Wu C, Cui C. et al. Molecular recognition-based DNA Nanoassemblies on the surfaces of Nanosized exosomes. J Am Chem Soc. 2017; 139: 5289-92. https://doi.org/10.1021/jacs.7b00319.

[170] Pham TC, Jayasinghe MK, Pham TT, Yang Y, Wei L, Usman WM. et al. Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J Extracell Vesicles. 2021; 10: e12057. https://doi.org/10.1002/jev2.12057.

[171] Pascucci L, Cocce V, Bonomi A, Ami D, Ceccarelli P, Ciusani E. et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery. J Control Release. 2014; 192: 262-70. https://doi.org/10.1016/j.jconrel.2014.07.042.

[172] Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K. et al. Exosome-mediated delivery of Hydrophobically modified siRNA for huntingtin mRNA silencing. Mol Ther. 2016; 24: 1836-47. https://doi.org/10.1038/mt.2016.126.

[173] Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC. et al. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011; 19: 1769-79. https://doi.org/10.1038/mt.2011.164.

[174] Betzer O, Perets N, Angel A, Motiei M, Sadan T, Yadid G. et al. In vivo neuroimaging of exosomes using gold nanoparticles. ACS Nano. 2017; 11: 10883-93. https://doi.org/10.1021/acsnano.7b04495.

[175] Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z. et al. Exosomes as drug delivery vehicles for Parkinson’s disease therapy. J Control Release. 2015; 207: 18-30. https://doi.org/10.1016/j.jconrel.2015.03.033.

[176] Lamichhane TN, Jeyaram A, Patel DB, Parajuli B, Livingston NK, Arumugasaamy N. et al. Oncogene knockdown via active loading of small RNAs into extracellular vesicles by sonication. Cell Mol Bioeng. 2016; 9: 315-24. https://doi.org/10.1007/s12195-016-0457-4.

[177] Xi XM, Xia SJ, Lu R. Drug loading techniques for exosome-based drug delivery systems. Pharmazie. 2021; 76: 61-7. https://doi.org/10.1691/ph.2021.0128.

[178] Fuhrmann G, Serio A, Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015; 205: 35-44. https://doi.org/10.1016/j.jconrel.2014.11.029.

[179] Goh WJ, Lee CK, Zou S, Woon EC, Czarny B, Pastorin G. Doxorubicin-loaded cell-derived nanovesicles: an alternative targeted approach for anti-tumor therapy. Int J Nanomedicine. 2017; 12: 2759-67. https://doi.org/10.2147/IJN.S131786.

[180] Li L, He D, Guo Q, Zhang Z, Ru D, Wang L. et al. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer. J Nanobiotechnology. 2022; 20: 50. https://doi.org/10.1186/s12951-022-01264-5.

[181] Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev. 2016; 99: 28-51. https://doi.org/10.1016/j.addr.2015.09.012.

[182] Amoozgar Z, Yeo Y. Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012; 4: 219-33. https://doi.org/10.1002/wnan.1157.

[183] Payandeh Z, Tangruksa B, Synnergren J, Heydarkhan-Hagvall S, Nordin JZ, Andaloussi SE. et al. Extracellular vesicles transport RNA between cells: Unraveling their dual role in diagnostics and therapeutics. Mol Asp Med. 2024; 99: 101302. https://doi.org/10.1016/j.mam.2024.101302.

[184] Matsumoto A, Takahashi Y, Nishikawa M, Sano K, Morishita M, Charoenviriyakul C. et al. Role of phosphatidylserine-derived negative surface charges in the recognition and uptake of intravenously injected B16BL6-derived exosomes by macrophages. J Pharm Sci. 2017; 106: 168-75. https://doi.org/10.1016/j.xphs.2016.07.022.

[185] Wei X, Liu S, Cao Y, Wang Z, Chen S. Polymers in engineering extracellular vesicle Mimetics: current status and prospective. Pharmaceutics. 2023; 15: 1496. https://doi.org/10.3390/pharmaceutics15051496.

[186] Dang XTT, Kavishka JM, Zhang DX, Pirisinu M, Le MTN. Extracellular vesicles as an efficient and versatile system for drug delivery. Cells. 2020; 9: 2191. https://doi.org/10.3390/cells9102191.

[187] Wiklander OP, Nordin JZ, O’Loughlin A, Gustafsson Y, Corso G, Mager I. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015; 4: 26316. https://doi.org/10.3402/jev.v4.26316.

[188] Cieslik M, Bryniarski K, Nazimek K. Biodelivery of therapeutic extracellular vesicles: should mononuclear phagocytes always be feared?Front Cell Dev Biol. 2023; 11: 1211833. https://doi.org/10.3389/fcell.2023.1211833.

[189] Yaddanapudi K, Meng S, Whitt AG, Al Rayyan N, Richie J, Tu A. et al. Exosomes from GM-CSF expressing embryonic stem cells are an effective prophylactic vaccine for cancer prevention. Onco Targets Ther. 2019; 8: 1561119. https://doi.org/10.1080/2162402X.2018.1561119.

[190] Meng S, Whitt AG, Tu A, Eaton JW, Li C, Yaddanapudi K. Isolation of exosome-enriched extracellular vesicles carrying granulocyte-macrophage Colony-stimulating factor from embryonic stem cells. J Vis Exp. 2021; 177: 60170. https://doi.org/10.3791/60170-v.

[191] Meng S, Whitt AG, Stamp BF, Eaton JW, Li C, Yaddanapudi K. Exosome-based cancer vaccine for prevention of lung cancer. Stem Cell Investig. 2023; 10: 2. https://doi.org/10.21037/sci-2022-030.

[192] Zhu Q, Ling X, Yang Y, Zhang J, Li Q, Niu X. et al. Embryonic stem cells-derived exosomes endowed with targeting properties as chemotherapeutics delivery vehicles for glioblastoma therapy. Adv Sci (Weinh). 2019; 6: 1801899. https://doi.org/10.1002/advs.201801899.

[193] Kalani A, Chaturvedi P, Kamat PK, Maldonado C, Bauer P, Joshua IG. et al. Curcumin-loaded embryonic stem cell exosomes restored neurovascular unit following ischemia-reperfusion injury. Int J Biochem Cell Biol. 2016; 79: 360-9. https://doi.org/10.1016/j.biocel.2016.09.002.

[194] Cui Y, Guo Y, Kong L, Shi J, Liu P, Li R. et al. A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis. Bioact Mater. 2022; 10: 207-21. https://doi.org/10.1016/j.bioactmat.2021.09.015.

[195] Tang Q, Lu B, He J, Chen X, Fu Q, Han H. et al. Exosomes-loaded thermosensitive hydrogels for corneal epithelium and stroma regeneration. Biomaterials. 2022; 280: 121320. https://doi.org/10.1016/j.biomaterials.2021.121320.

[196] Sun B, Kitchen S, Tang N, Garza A, Jacob S, Pulliam L. Engineered induced-pluripotent stem cell derived monocyte extracellular vesicles alter inflammation in HIV humanized mice. Extracell Vesicles Circ Nucl Acids. 2022; 3: 118-32. https://doi.org/10.20517/evcna.2022.11.

[197] Kmiotek-Wasylewska K, Bobis-Wozowicz S, Karnas E, Orpel M, Woznicka O, Madeja Z. et al. Anti-inflammatory, anti-fibrotic and pro-cardiomyogenic effects of genetically engineered extracellular vesicles enriched in miR-1 and miR-199a on human cardiac fibroblasts. Stem Cell Rev Rep. 2023; 19: 2756-73. https://doi.org/10.1007/s12015-023-10621-2.

[198] Winston CN, Aulston B, Rockenstein EM, Adame A, Prikhodko O, Dave KN. et al. Neuronal exosome-derived human tau is toxic to recipient mouse neurons in vivo. J Alzheimers Dis. 2019; 67: 541-53. https://doi.org/10.3233/JAD-180776.

[199] Chung YH, Ho YP, Farn SS, Tsai WC, Li ZX, Lin TY. et al. In vivo SPECT imaging of Tc-99 m radiolabeled exosomes from human umbilical-cord derived mesenchymal stem cells in small animals. Biom J. 2024; 47: 100721. https://doi.org/10.1016/j.bj.2024.100721.

[200] Han Z, Liu S, Pei Y, Ding Z, Li Y, Wang X. et al. Highly efficient magnetic labelling allows MRI tracking of the homing of stem cell-derived extracellular vesicles following systemic delivery. J Extracell Vesicles. 2021; 10: e12054. https://doi.org/10.1002/jev2.12054.

[201] Liu C, Helsper S, Marzano M, Chen X, Muok L, Esmonde C. et al. Human forebrain organoid-derived extracellular vesicle Labeling with iron oxides for in vitro magnetic resonance imaging. Biomedicines. 2022; 10: 3060. https://doi.org/10.3390/biomedicines10123060.

[202] Ju Y, Hu Y, Yang P, Xie X, Fang B. Extracellular vesicle-loaded hydrogels for tissue repair and regeneration. Mater Today Bio. 2023; 18: 100522. https://doi.org/10.1016/j.mtbio.2022.100522.

[203] Liu B, Lee BW, Nakanishi K, Villasante A, Williamson R, Metz J. et al. Cardiac recovery via extended cell-free delivery of extracellular vesicles secreted by cardiomyocytes derived from induced pluripotent stem cells. Nat Biomed Eng. 2018; 2: 293-303. https://doi.org/10.1038/s41551-018-0229-7.

[204] Cedillo-Servin G, Louro AF, Gamelas B, Meliciano A, Zijl A, Alves PM. et al. Microfiber-reinforced hydrogels prolong the release of human induced pluripotent stem cell-derived extracellular vesicles to promote endothelial migration. Biomater Adv. 2023; 155: 213692. https://doi.org/10.1016/j.bioadv.2023.213692.

[205] Jarrige M, Frank E, Herardot E, Martineau S, Darle A, Benabides M. et al. The future of regenerative medicine: cell therapy using pluripotent stem cells and acellular therapies based on extracellular vesicles. Cells. 2021; 10: 240. https://doi.org/10.3390/cells10020240.